# Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes

> **NCT03344692** · PHASE3 · COMPLETED · sponsor: **Nantes University Hospital** · enrollment: 22 (actual)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** Alirocumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03344692
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-12
- **Primary completion:** 2022-04-28
- **Final completion:** 2022-04-28
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344692, "Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03344692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*